Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 12;7(7):CD012556.
doi: 10.1002/14651858.CD012556.pub2.

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer)

Marius Goldkuhle  1 , Maria Dimaki, Gerald Gartlehner, Ina Monsef, Philipp Dahm, Jan-Peter Glossmann, Andreas Engert, Bastian von Tresckow, Nicole Skoetz
Affiliations

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer)

Marius Goldkuhle et al. Cochrane Database Syst Rev. .

Abstract

Background: Hodgkin's lymphoma (HL) is a cancer of the lymphatic system, and involves the lymph nodes, spleen and other organs such as the liver, lung, bone or bone marrow, depending on the tumour stage. With cure rates of up to 90%, HL is one of the most curable cancers worldwide. Approximately 10% of people with HL will be refractory to initial treatment or will relapse; this is more common in people with advanced stage or bulky disease. Standard of care for these people is high-dose chemotherapy and autologous stem cell transplantation (ASCT), but only 55% of participants treated with high-dose chemotherapy and ASCT are free from treatment failure at three years, with an overall survival (OS) of about 80% at three years.Checkpoint inhibitors that target the interaction of the programmed death (PD)-1 immune checkpoint receptor, and its ligands PD-L1 and PD-L2, have shown remarkable activity in a wide range of malignancies. Nivolumab is an anti-(PD)-1 monoclonal antibody and currently approved by the US Food and Drug Administration (FDA) for the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma and, since 2016, for classical Hodgkin's lymphoma (cHL) after treatment with ASCT and brentuximab vedotin.

Objectives: To assess the benefits and harms of nivolumab in adults with HL (irrespective of stage of disease).

Search methods: We searched CENTRAL, MEDLINE, Embase, International Pharmaceutical Abstracts, conference proceedings and six study registries from January 2000 to May 2018 for prospectively planned trials evaluating nivolumab.

Selection criteria: We included prospectively planned trials evaluating nivolumab in adults with HL. We excluded trials in which less than 80% of participants had HL, unless the trial authors provided the subgroup data for these participants in the publication or after we contacted the trial authors.

Data collection and analysis: Two review authors independently extracted data and assessed potential risk of bias. We used the software RobotReviewer to extract data and compared results with our findings. As we did not identify any randomised controlled trials (RCTs) or non-RCTs, we did not meta-analyse data.

Main results: Our search found 782 potentially relevant references. From these, we included three trials without a control group, with 283 participants. In addition, we identified 14 ongoing trials evaluating nivolumab, of which two are randomised. Risk of bias of the three included studies was moderate to high. All of the participants were in relapsed stage, most of them were heavily pretreated and had received at least two previous treatments, most of them had also undergone ASCT. As we did not identify any RCTs, we could not use the software RobotReviewer to assess risk of bias. The software identified correctly that one study was not an RCT and did not extract any trial data, but extracted characteristics of the other two studies (although also not RCTs) in a sufficient way.Two studies with 260 participants evaluated OS. After six months, OS was 100% in one study and median OS (the timepoint when only 50% of participants were alive) was not reached in the other trial after a median follow-up of 18 months (interquartile range (IQR) 15 to 22 months) (very low certainty evidence, due to observational trial design, heterogenous patient population in terms of pretreatments and various follow-up times (downgrading by 1 point)). In one study, one out of three cohorts reported quality of life. It was unclear whether there was an effect on quality of life as only a subset of participants filled out the follow-up questionnaire (very low certainty evidence). Three trials (283 participants) evaluated progression-free survival (PFS) (very low certainty evidence). Six-month PFS ranged between 60% and 86%, and median PFS ranged between 12 and 18 months. All three trials (283 participants) reported complete response rates, ranging from 12% to 29%, depending on inclusion criteria and participants' previous treatments (very low certainty evidence).One trial (243 participants) reported drug-related grade 3 or 4 adverse events (AEs) only after a median follow-up of 18 months (IQR 15 to 22 months); these were fatigue (23%), diarrhoea (15%), infusion reactions (14%) and rash (12%). The other two trials (40 participants) reported 23% to 52% grade 3 or 4 AEs after six months' follow-up (very low certainty evidence). Only one trial (243 participants) reported drug-related serious AEs; 2% of participants developed infusion reactions and 1% pneumonitis (very low certainty evidence).None of the studies reported treatment-related mortality.

Authors' conclusions: To date, data on OS, quality of life, PFS, response rate, or short- and long-term AEs are available from small uncontrolled trials only. The three trials included heavily pretreated participants, which had previously undergone regimens of BV or ASCT. For these participants, median OS was not reached after follow-up times of at least 16 months (more than 50% of participants with a limited life expectancy were alive at this timepoint). Only one cohort out of three only reported quality of life, with limited follow-up data so that meaningful conclusions were not possible. Serious adverse events occurred rarely. Currently, data are too sparse to make a clear statement on nivolumab for people with relapsed or refractory HL except for heavily pretreated people, which had previously undergone regimens of BV or ASCT. When interpreting these results, it is important to consider that proper RCTs should confirm these findings.As there are 14 ongoing trials evaluating nivolumab, of which two are RCTs, it is possible that an update of this review will be published in the near future and that this update will show different results to those reported here.

PubMed Disclaimer

Conflict of interest statement

MG: none known.

MD: none known.

GG: none known.

IM: none known.

PD: none known.

JPG: none known.

AE: none known.

BvT: received travel grants, scientific grants, personal fees and non‐financial support from Novartis; travel grants, scientific grants, personal fees and non‐financial support from Takeda; personal fees from Amgen; personal fees from Celgene; scientific grants and personal fees from MSD; and a travel grant from Bristol‐Myers Squibb.

NS: none known.

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD012556

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

CheckMate 039 {published data only}
    1. Ansell S, Armand P, Timmerman J, Shipp M, Popa McKiver M, Zhu L, et al. Nivolumab re‐treatment in patients with relapsed/refractory Hodgkin lymphoma: safety and efficacy outcomes from a phase 1 clinical trial. Haematologica. 2016; Vol. 101:49.
    1. Ansell S, Armand P, Timmerman JM, Shipp MA, Garelik MBB, Zhu L, et al. Nivolumab in patients (PTS) with relapsed or refractory classical Hodgkin lymphoma (R/R Chl): clinical outcomes from extended follow‐up of a phase 1 study (CA209‐039). Blood. 2015; Vol. 126, issue 23:583.
    1. Ansell S, Gutierrez ME, Shipp MA, Gladstone D, Moskowitz A, Borello I, et al. A phase 1 study of nivolumab in combination with Ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood. 2016; Vol. 128, issue 22:183.
    1. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD‐1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine 2015;372(4):308‐9. - PMC - PubMed
    1. Armand P, Ansell SM, Lesokhin AM, Halwani A, Millenson MM, Schuster SJ, et al. Nivolumab in patients with relapsed or refractory Hodgkin lymphoma‐preliminary safety, efficacy and biomarker results of a phase I study. Blood. 2014; Vol. 124:21.
CheckMate 205 {published data only}
    1. Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani P L, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow‐up of the multicohort single‐arm phase II CheckMate 205 Trial. Journal of Clinical Oncology 2018;36(14):1428‐39. - PMC - PubMed
    1. Armand P, Shipp MA, Kuruvilla J, Collins GP, Ramchandren R, Timmerman J, et al. A phase 2 study of a nivolumab (nivo)‐containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): study 205 Cohort D. Journal of Clinical Oncology. 2016; Vol. 34:15.
    1. Engert A, Fanale M, Santoro A, Armand P, Ansell S, Zinzani P L, et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the multicohort multicenter phase 2 CheckMate 205 trial. Haematologica. 2017; Vol. 102:145.
    1. Engert A, Hirji I, Taylor F, Bennett B, Cocks K, Kato K, et al. Quality‐of‐life outcomes in patients with classical Hodgkin lymphoma treated with nivolumab monotherapy in CheckMate 205 (cohort B), a phase 2 study. Haematologica. 2016; Vol. 101:73.
    1. Engert A, Santoro A, Shipp M, Zinzani PL, Timmerman J, Ansell S, et al. CheckMate 205: a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma following autologous stem cell transplantation and brentuximab vedotin. Haematologica 2016;101:319.
Hatake 2016 {published data only}
    1. Hatake K, Kinoshita T, Fukuhara N, Choi I, Taniwaki M, Ando K, et al. Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO‐4538‐15): an interim analysis. Journal of Clinical Oncology. 2016; Vol. 34.
    1. Maruyama D, Hatake K, Kinoshita T, Fukuhara N, Choi I, Taniwaki M, et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Science 2017;108(5):1007‐12. - PMC - PubMed

References to studies excluded from this review

Armand 2016 {published data only}
    1. Armand P, Brody J, Barr PM, Shustov AR, Moskowitz AJ, Kline JP, et al. A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30‐expressing relapsed/refractory non‐Hodgkin lymphomas (NHLs). Journal of Clinical Oncology. 2016; Vol. 34.
Falchi 2016 {published data only}
    1. Falchi L, Sawas A, Deng C, Amengual JE, Lichtenstein E, Khan K, et al. PD‐1 blockade after epigenetic therapy in patients with relapsed or refractory Hodgkin lymphoma: higher‐than‐expected rate of complete responses. Blood 2016;128:2999. - PMC - PubMed
Herbaux 2015 {published data only}
    1. Herbaux C, Gauthier J, Brice P, Fornecker L, Bouabdallah K, Manson G, et al. Nivolumab is effective and reasonably safe in relapsed or refractory Hodgkin's lymphoma after allogeneic hematopoietic cell transplantation: a study from the LYSA and SFGM‐TC. Blood 2015;126:3979.
Merryman 2017 {published data only}
    1. Merryman RW, Kim HT, Zinzani PL, Carlo‐Stella C, Ansell SM, Perales MA, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD‐1 blockade in relapsed/refractory lymphoma. Blood 2017;129(10):1380‐8. - PMC - PubMed
Yared 2016 {published data only}
    1. Yared JA, Hardy N, Singh Z, Hajj S, Badros AZ, Kocoglu M, et al. Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplantation 2016;51:850‐2. - PubMed

References to ongoing studies

NCT01822509 {published data only}
    1. Ipilimumab or nivolumab in treating adults with relapsed hematologic malignancies after donor stem cell transplant. Ongoing study 9 April 2013; planned primary completion date: 31 December 2018.
NCT01896999 {published and unpublished data}
    1. Diefenbach CS, Hong F, David K, Cohen J, Roberston M, Advani R, et al. Safety and efficacy of combination of brentuximab vedotin and nivolumab in relapsed/refractory Hodgkin lymphoma: a trial of the ECOG‐ACRIN Cancer Research Group (E4412). Hematological Oncology 2017;35:84‐5.
    1. Diefenbach CS, Hong F, David KA, Cohen J, Robertson M, Advani R, et al. A phase I study with an expansion cohort of the combination of ipilimumab and nivolumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: a trial of the ECOG‐ACRIN Cancer Research Group (E4412 Arms D and E). Blood 2016;128(22):1106.
    1. Diefenbach CSM, Hong F, Ambinder RF, Cohen JB, Robertson MJ, Fenske TS, et al. A phase I study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: a trial of the ECOG‐ACRIN Cancer Research Group (E4412). Haematologica 2016;101:44‐5.
NCT02408861 {published data only}
    1. Nivolumab and ipilimumab in treating adults with HIV associated relapsed or refractory classical Hodgkin's lymphoma or solid tumours that are metastatic or cannot be removed by surgery. Ongoing study 27 August 2015; estimated primary completion date: 31 December 2020.
NCT02572167 {published and unpublished data}
    1. Herrera AF, Bartlett NL, Ramchandren R, Vose JM, Moskowitz AJ, Feldman TA, et al. Preliminary results from a phase 1/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 2016;128(22):1105.
    1. Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, et al. Interim results from a phase 1/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Hematological Oncology 2017;35:85‐6.
    1. Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 2018;131(11):1183‐94. - PMC - PubMed
NCT02758717 {published data only}
    1. Phase II, multi‐center trial of nivolumab and brentuximab vedotin in individuals with untreated Hodgkin lymphoma over the age of 60 years or unable to receive standard adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy. Ongoing study 13 May 2016; estimated primary completion date: 13 November 2019.
NCT02927769 {published data only}
    1. A phase I study of ipilimumab and nivolumab in advanced HIV‐associated solid tumours with expansion cohorts in HIV‐associated solid tumours and a cohort of HIV‐associated classical Hodgkin's lymphoma. Ongoing study 27 August 2015; estimated primary completion date: 31 December 2020.
NCT02940301 {published data only}
    1. Ibrutinib and nivolumab in treating adults with relapsed or refractory classical Hodgkin's lymphoma. Ongoing study 20 December 2016; estimated primary completion date: 31 May 2019 (final data collection date for primary outcome).
NCT02973113 {published data only}
    1. Nivolumab with Epstein Barr virus specific T cells (EB‐VSTS), relapsed/refractory EBV positive lymphoma (PREVALE). Ongoing study 16 February 12016; estimated primary completion date: 16 April 2019 (final data collection date for primary outcome).
NCT03004833 {published data only}
    1. Nivolumab and AVD in early‐stage unfavourable classical Hodgkin lymphoma (NIVAHL). Ongoing study 21 February 2017; estimated primary completion date: December 2018 (final data collection date for primary outcome).
NCT03016871 {published data only}
    1. Nivolumab, ifosfamide, carboplatin, and etoposide as second‐line therapy in treating adults with refractory or relapsed Hodgkin lymphoma. Ongoing study 8 May 2017; estimated primary completion date: 24 April 2019 (final data collection date for primary outcome).
NCT03033914 {published data only}
    1. (B)VD followed by nivolumab as frontline therapy for higher risk patients with classical Hodgkin lymphoma. Ongoing study 25 January 2017; estimated primary completion date: January 2020 (final data collection date for primary outcome).
NCT03057795 {published data only}
    1. Nivolumab and brentuximab vedotin after stem cell transplant in treating patients with relapsed or refractory high‐risk classical Hodgkin lymphoma. Ongoing study 3 May 2017; estimated primary completion date: April 2019 (final data collection date for primary outcome).
NCT03138499 {published data only}
    1. A study of nivolumab plus brentuximab vedotin versus brentuximab vedotin alone in patients with advanced stage classical Hodgkin lymphoma, who are relapsed/ refractory or who are not eligible for autologous stem cell transplant (CheckMate 812). Ongoing study 16 May 2017; estimated primary completion date: 29 November 2020 (final data collection date for primary outcome).
NCT03161613 {published data only}
    1. Study to assess the safety of nivolumab in the treatment of metastatic melanoma, lung cancer, renal cancer, squamous cell carcinoma of the head and neck, and chronic Hodgkin's lymphoma in adults in Mexico. Ongoing study 17 July 2017; estimated primary completion date: 1 April 2019 (final data collection date for primary outcome).

Additional references

Aaronson 1993
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ‐C30: a quality‐of‐life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute 1993;85(5):365‐76. [PUBMED: 8433390] - PubMed
Ansell 2015
    1. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD‐1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine 2015;372(4):311‐9. - PMC - PubMed
Ansell 2016
    1. Ansell S, Gutierrez ME, Shipp MA, Gladstone D, Moskowitz A, Borello I, et al. A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). 58th ASH Annual Meeting; Dec 3‐6; San Diego (CA). 2016.
Borchmann 2011
    1. Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, et al. Eight cycles of escalated‐dose BEACOPP compared with four cycles of escalated‐dose BEACOPP followed by four cycles of baseline‐dose BEACOPP with or without radiotherapy in patients with advanced‐stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. Journal of Clinical Oncology 2011;29(32):4234‐42. [PUBMED: 21990399] - PubMed
Brahmer 2015
    1. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous‐cell non‐small‐cell lung cancer. New England Journal of Medicine 2015;373(2):123‐35. [PUBMED: 26028407] - PMC - PubMed
Broeckelmann 2017
    1. Broeckelmann P, Mueller H, Kücüksarioglan E, Kaskel P, Metterlein V, Giezeck H, et al. Clinical outcomes of patients with 3rd or higher relapsed classical Hodgkin lymphoma: results from the German Hodgkin Study Group. Blood 2017;130(Suppl 1):2793‐93. - PubMed
Brooks 1996
    1. Brooks R. EuroQol: the current state of play. Health Policy (Amsterdam, Netherlands) 1996;37(1):53‐72. [PUBMED: 10158943] - PubMed
Canellos 1992
    1. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. New England Journal of Medicine 1992;327(21):1478‐84. [PUBMED: 1383821] - PubMed
Chen 2016
    1. Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Five‐year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 2016;128(12):1562‐6. [PUBMED: 27432875] - PMC - PubMed
Cheson 2014
    1. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non‐Hodgkin lymphoma: the Lugano classification. Journal of Clinical Oncology 2014;32(27):3059‐68. [PUBMED: 25113753] - PMC - PubMed
Connors 2009
    1. Connors JM. Clinical manifestations and natural history of Hodgkin's lymphoma. Cancer Journal 2009;15(2):124‐8. - PubMed
Covidence 2016 [Computer program]
    1. Veritas Health Innovation. Covidence systematic review software. Melbourne, Australia: Veritas Health Innovation, Available at www.covidence.org.
Deeks 2011
    1. Deeks JJ, Higgins JP, Altman DG. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Engert 2003
    1. Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, et al. Involved‐field radiotherapy is equally effective and less toxic compared with extended‐field radiotherapy after four cycles of chemotherapy in patients with early‐stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology 2003;21(19):3601‐8. - PubMed
Engert 2007
    1. Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended‐field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. Journal of Clinical Oncology 2007;25(23):3495‐502. - PubMed
Engert 2010
    1. Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, et al. Reduced treatment intensity in patients with early‐stage Hodgkin's lymphoma. New England Journal of Medicine 2010;363(7):640‐52. [PUBMED: 20818855] - PubMed
Engert 2012
    1. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced‐intensity chemotherapy and PET‐guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open‐label, phase 3 non‐inferiority trial. Lancet 2012;379(9828):1791‐9. [PUBMED: 22480758] - PubMed
GRADEpro GDT 2014 [Computer program]
    1. GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed February 2017. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Green 2012
    1. Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, et al. Constitutive AP‐1 activity and EBV infection induce PD‐L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clinical Cancer Research 2012;18(6):1611‐8. [PUBMED: 22271878] - PMC - PubMed
Hamid 2013
    1. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti‐PD‐1) in melanoma. New England Journal of Medicine 2013;369(2):134‐44. [PUBMED: 23724846] - PMC - PubMed
Higgins 2011a
    1. Higgins JP, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins 2011b
    1. Higgins JP, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Iwai 2002
    1. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD‐L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD‐L1 blockade. Proceedings of the National Academy of Sciences of the United States of America 2002;99(19):12293‐7. - PMC - PubMed
Küppers 2009
    1. Küppers R. The biology of Hodgkin's lymphoma. Nature Reviews. Cancer 2009;9(1):15‐27. [PUBMED: 19078975] - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Lister 1989
    1. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. Journal of Clinical Oncology 1989;7(11):1630‐6. - PubMed
Marshall 2016
    1. Marshall IJ, Kuiper J, Wallace B C. RobotReviewer: evaluation of a system for automatically assessing bias in clinical trials. Journal of the American Medical Informatics Association 2016;23(1):193‐201. - PMC - PubMed
Mathas 2016
    1. Mathas S, Hartmann S, Küppers R. Hodgkin lymphoma: Pathology and biology. Seminars in Hematology 2016;53(3):139‐47. [PUBMED: 27496304] - PubMed
Matsuki 2016
    1. Matsuki E, Younes A. Checkpoint inhibitors and other immune therapies for Hodgkin and non‐Hodgkin lymphoma. Current Treatment Options in Oncology 2016;17(6):31. - PMC - PubMed
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. Journal of Clinical Epidemiology 2009;62(10):1006‐12. [PUBMED: 19631508] - PubMed
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34. [PUBMED: 9921604] - PubMed
Pileri 2002
    1. Pileri SA, Ascani S, Leoncini L, Sabattini E, Zinzani PL, Piccaluga PP, et al. Hodgkin's lymphoma: the pathologist's viewpoint. Journal of Clinical Pathology 2002;55(3):162‐76. [PUBMED: 11896065] - PMC - PubMed
Rancea 2013
    1. Rancea M, Monsef I, Tresckow B, Engert A, Skoetz N. High‐dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD009411.pub2; PUBMED: 23784872] - DOI - PMC - PubMed
Re 2005
    1. Re D, Thomas RK, Behringer K, Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 2005;105(12):4553‐60. [PUBMED: 15728122] - PubMed
Reeves 2011
    1. Reeves BC, Deeks JJ, Higgins JP, Wells GA. Chapter 13: Including non‐randomized studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Review Manager 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
RobotReviewer 2015 [Computer program]
    1. Marshall IJ, Kuiper J, Wallace BC. RobotReviewer. Version accessed February 2017 2015. Available at www.robotreviewer.net.
Roemer 2016
    1. Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, et al. PD‐L1 and PD‐L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. Journal of Clinical Oncology 2016;34(23):2690‐7. [PUBMED: 27069084] - PMC - PubMed
Rosenberg 1971
    1. Rosenberg SA, Boiron M, DeVita VT Jr, Johnson RE, Lee BJ, Ultmann JE, et al. Report of the Committee on Hodgkin's Disease Staging Procedures. Cancer Research 1971;31(11):1862‐3. [PUBMED: 5121695] - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings tables'. In: Higgins JP, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Schünemann 2016
    1. Schünemann HJ, Mustafa R, Brozek J, Santesso N, Alonso‐Coello P, Guyatt G, et al. GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. Journal of Clinical Epidemiology 2016;76:89‐98. - PubMed
Skoetz 2013
    1. Skoetz N, Trelle S, Rancea M, Haverkamp H, Diehl V, Engert A, et al. Effect of initial treatment strategy on survival of patients with advanced‐stage Hodgkin's lymphoma: a systematic review and network meta‐analysis. Lancet Oncology 2013;14(10):943‐52. [PUBMED: 23948348] - PubMed
Sterne 2011
    1. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Sterne 2016
    1. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ 2016;355:i4919. - PMC - PubMed
Thomas 2002
    1. Thomas RK, Re D, Zander T, Wolf J, Diehl V. Epidemiology and etiology of Hodgkin's lymphoma. Annals of Oncology 2002;13 Suppl 4:147‐52. [PUBMED: 12401681] - PubMed
Tierney 2007
    1. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials 2007;8:16. [PUBMED: 17555582] - PMC - PubMed
Timmermann 2016
    1. Timmerman J, Engert A, Younes A, Santoro A, Armand P, Fanale MA, et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128:1110.
von Tresckow 2012
    1. Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin study group HD14 trial. Journal of Clinical Oncology 2012;30(9):907‐13. [PUBMED: 22271480] - PubMed
Younes 2012
    1. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. Journal of Clinical Oncology 2012;30(18):2183‐9. [PUBMED: 22454421] - PMC - PubMed
Younes 2016
    1. Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial. Lancet Oncology 2016;17(9):1283‐94. - PMC - PubMed

References to other published versions of this review

Skoetz 2017
    1. Skoetz N, Goldkuhle M, Gartlehner G, Monsef I, Dahm P, Glossmann J‐P, et al. Nivolumab for adult individuals with Hodgkin lymphoma (an exemplar rapid review using RobotReviewer). Cochrane Database of Systematic Reviews 2017, Issue 2. [DOI: 10.1002/14651858.CD012556] - DOI - PMC - PubMed

Publication types